OCS Oculis Holding AG

$OCS Don't let algorithms shake you out at the absolute bottom. The facts: 💎 MID-2029 CASH FORTRESS: Management confirmed cash is fully secured into the second half of 2029 (~$282M). Bankruptcy or toxic financing is impossible. 🎯 $39.00 PRICE TARGET: H.C. Wainwright explicitly backed a $39 target. That is nearly 500% upside from current levels. 🧪 NOV 5th CATALYST: The upcoming earnings call and late-stage pipeline data for Privosegtor (PIONEER) and Licaminlimab are the real multi-billion dollar plays. Shorts are trapping themselves at 52-week lows. Load up, ignore the short-term noise, and wait for the reversal! 🚀🔥 #BiotechSqueeze

$OCS Smells like tax loss selling. Near term catalysts are sort of boring, but I think completion of enrollment (later this quarter?) of PREDICT-1 Licaminlimab for DED will be regarded as positive and stop the price decline. This is a good chance Licaminlimab meets it's trial goals, so the stock will not be cheap after that. I'll buy some in early november if I can find the cash. That's when I think the stock price will near a low.

$OCS • Capital Security to H2 2029: With a reported $282.3M in cash and short-term investments, management has guided a secure operational runway into late 2029. This completely immunizes the company against near-term insolvency or toxic, distressed financing cycles. • H.C. Wainwright Institutional Conviction: On September 18th, H.C. Wainwright explicitly backed a $39.00 price target. This represents an asymmetric valuation gap compared to current technical liquidation levels, reflecting the long-term enterprise value of the remaining assets. • Clear Pipeline Horizons: While the upcoming November 5th operational update will outline corporate progression, the true fundamental inflections rest on the advanced pipeline. The market is completely discounting the clinical potential of the PIONEER program (Privosegtor) for optic neuritis and the PREDICT-1 trial (Licaminlimab).